News
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the ...
Slideshows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback